Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells by Lindsey A. Murphy, Amanda C. Winters

Get full text

Molecular measurable residual disease: staring at red herrings by Amanda C. Winters, Daniel A. Pollyea

Get full text

Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/aza... by Amanda C. Winters, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Grace Bosma, Diana Abbott, Nicholas Miltgen, Ji Yuan, Amy L. Treece, Bradford J. Siegele, Mark D. Ewalt, Jonathan A. Gutman, Craig T. Jordan, Daniel A. Pollyea

Get full text

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia by Amanda C. Winters, Jonathan A. Gutman, Enkhtsetseg Purev, Molly Nakic, Jennifer Tobin, Stephanie Chase, Jeff Kaiser, Lindsey Lyle, Chelsey Boggs, Keri Halsema, Jeffrey T. Schowinsky, Julie Rosser, Mark D. Ewalt, Bradford Siegele, Vishal Rana, Steven Schuster, Diana Abbott, Brett M. Stevens, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea

Get full text